

1 **Efficient rescue of a newly classified Ebinur lake orthobunyavirus** 2 **with GFP reporter and its application in rapid antiviral screening**

3 Nanjie Ren^{1,2,#}, Fei Wang^{1,#}, Lu Zhao³, Shunlong Wang^{1,2}, Guilin Zhang⁴, Jiaqi Li^{1,2},
4 Bo Zhang^{1,2}, Eric Bergeron⁵, Zhiming Yuan^{1,2,*}, Han Xia^{1,2,*}

5
6 1. Key Laboratory of Special Pathogens and Biosafety, Wuhan Institute of Virology,
7 Chinese Academy of Sciences, Wuhan, Hubei, China

8 2. University of Chinese Academy of Sciences, Beijing, China

9 3. Institute of Biology, Westlake institute for Advanced Study, School of Life
10 sciences, Westlake University, Zhejiang, China

11 4. Xinjiang Heribase Biotechnology CO., LTD., Urumqi, China

12 5. Viral Special Pathogens Branch, Division of High-Consequence Pathogens and
13 Pathology, National Center for Emerging and Zoonotic Infectious Diseases, Centers
14 for Disease Control and Prevention, Atlanta, United States

15

16 *Corresponding authors: Zhiming Yuan (yzm@wh.iov.cn) and Han Xia
17 (hanxia@wh.iov.cn)

18 # These authors contributed equally to this work.

19

20 **Abstract**

21 Orthobunyaviruses have been reported to cause severe diseases in humans or animals,
22 posing a threat to human health and social economy. Ebinur lake virus (EBIV) is a
23 newly classified orthobunyavirus, which needs further intensive study and therapies to
24 cope with its potential infection risk to human and animals. Here, through the reverse
25 genetics system, the recombinant EBIV of wild type (rEBIV/WT) and
26 NP-conjugated-eGFP (rEBIV/eGFP/S) were rescued for the application of the rapid
27 antiviral drug screening. The eGFP fluorescence signal of the rEBIV/eGFP/S was
28 stable in the process of successive passage in BHK-21 cells (over 10 passages) and
29 this recombinant virus could replicate in various cell lines. Compared to the wild type
30 EBIV, the rEBIV/eGFP/S caused the smaller plaques and its peak titers were lower,
31 suggesting attenuation due to the eGFP insertion. Through the high-content screening

(HCS) system, ribavirin showed an inhibitory effect on the rEBIV/eGFP/S with an EC₅₀ of 21.91 μ M, while favipiravir did not inhibit, even at high concentrations. In addition, five of ninety-six natural compounds had antiviral against EBIV. The robust reverse genetics system for EBIV will facilitate investigation into replication and assembly mechanisms and assist drug and vaccine development.

Keyword: *Orthobunyavirus*; Ebinur lake virus; reverse genetic system; reporter virus; high-content screening; antiviral drugs

1 Introduction

Emerging and re-emerging arboviruses pose a big threat to human and animal health worldwide (1). The genus *Orthobunyavirus* (family *Peribunyaviridae*) includes over 18 serogroups is the largest genus in the order *Bunyavirales*, comprising over 170 arboviruses which were mainly transmitted through mosquito vectors (2)(3). These negative-sense RNA viruses take their name from Bunyamwera virus (BUNV), which was originally isolated in 1943 from *Aedes* mosquitoes during an investigation of yellow fever in the Semliki Forest, Uganda (4). Some members of *Orthobunyavirus* can result in several disease syndromes in humans, including acute but self-limiting febrile illness (Oropouche virus (OROV)) (5), pediatric arboviral encephalitis (La Crosse virus (LACV)) (6) and haemorrhagic fever (Ngari virus (NRIV)) (7). Apart from human pathogens, orthobunyaviruses comprises some veterinary pathogens, such as Akabane virus (AKAV) and Schmallenberg virus (SBV), which both cause congenital malformations in ruminants (8)(9).

Orthobunyaviruses are tri-segmented negative-sense RNA viruses, comprising small (S), medium (M), and large (L) segments (4), named by the segment length. The *L* segment encodes the viral RNA-dependent RNA polymerase (RdRp), which involved in the genome replication. The *M* segment encodes two structural glycoproteins, Gn and Gc, and a non-structural protein (NSm). Gn and Gc are related to receptor binding and the fusion of the viral and endosomal membranes (10). The

61 NSm was suggested to function as a scaffold for virion assembly (11). The *S* segment
62 encodes the nucleocapsid protein (N) and a non-structural protein (NSs) in
63 overlapping open reading frames with the same direction. The N protein encapsidates
64 both genomic and antigenomic RNA (but not viral mRNA) to form ribonucleoprotein
65 (RNPs) complexes that are the templates for the viral RdRp (4)(12). The NSs protein
66 is considered as the major virulence determinant of orthobunyaviruses by antagonizing
67 host innate immune responses, including type I interferon responses (13)(14).

68 Reverse genetic systems are powerful and versatile molecular tools for the study of
69 RNA viruses, which can be used to produce attenuated virus vaccine (15), probe viral
70 replication and interactions with host innate immune responses (4). Since the BUNV
71 was recovered from transfecting cells with just three plasmids that express full-length
72 antigenome viral RNAs in 2004 (16), the infectious cDNA clones have been obtained
73 for several orthobunyaviruses, such as SBV (17), LACV (18), AKBV (19) and Shuni
74 virus (SHNV) (10). According to the previous researches, we can find that two
75 transcription plasmids for the reverse systems have been developed: (1) transcription
76 plasmids based on T7 promoter which could be recognized by T7 RNA polymerase;
77 (2) transcription plasmids using mammalian RNA polymerase I promoters (4).
78 Considering the efficiency of RNA polymerase I-driven system was lower than that of
79 T7 RNA polymerase (19), the latter was chosen in our study.

80 Ebinur lake virus (EBIV) is isolated from *Culex modestus* mosquito pools in Ebinur
81 lake region, Xinjiang in 2014 (20). Our previous work demonstrates that EBIV has
82 the highest similarity with Germiston virus (GERV) (21), which belongs to risk group
83 3 human pathogens. Remarkably, EBIV can cause acute lethal disease in adult mice
84 (22), and the antibodies against EBIV are detected in local residents, which indicate
85 that EBIV has a potential infection risk in animal and/or human (21). Hence, we use
86 the reverse genetics system to rescue the recombinant EBIV of wild type (rEBIV/WT)
87 and NP-conjugated-eGFP (rEBIV/eGFP/S). Furthermore, through the high-content
88 screening (HCS) system, ribavirin and five natural compounds was found to have the
89 antiviral effects against the recombinant EBIV.

2 Methods and Materials

2.1 Cells, viruses and antibodies

Baby hamster kidney cell (BHK-21), African green monkey kidney cells (Vero E6), human adrenal cortical carcinoma cells (SW13), and porcine kidney epithelial cells (PK15) were propagated in Dulbecco's modified Eagle's medium (DMEM, Gibco) supplemented with 10% fetal bovine serum (FBS, Gibco), 100 units/mL of penicillin and 100 µg/mL of streptomycin. BSR-T7 cell, a generous gift from Prof. Bo Zhang, which could express T7 RNA polymerase, were cultured in DMEM supplemented with 10% FBS and 1 mg/mL G418 (Beyotime). All mammalian cells were grown at 37 °C under a 5% CO₂ atmosphere. The chicken hepatocellular carcinoma cell line (LMH) was maintained in Dulbecco's Modified Eagle Medium/Nutrient Mixture F-12 (DME/F-12, HyClone) containing 10% FBS and 1% penicillin/streptomycin at 37 °C in 5% CO₂. The *Aedes albopictus* mosquito cell (C6/36) was grown in Roswell Park Memorial Institute (RPMI) 1640 medium supplemented with 10% FBS and 1% penicillin/streptomycin, and were maintained in 5% CO₂ at 28 °C.

EBIV isolate Cu20-XJ was first isolated from *Culex modestus* mosquitoes in Xinjiang, China (20). The EBIV virus stock was propagated in BHK-21 cells in DMEM containing 2% FBS, subpackaged and stored at -80 °C. The rEBIV/WT and reporter virus rEBIV/eGFP/S were produced through the transfection of the plasmids (described below) into BSR-T7 cells with transcription plasmids (described below). All the work with infectious virus were conducted in the biosafety level-2 (BSL-2) laboratory.

The mouse polyclonal antibody against EBIV N protein was generated by immunization of BALB/C mice with the purified EBIV N protein. Alexa FluorTM 594 goat anti-mouse IgG (H+L) used as secondary antibody was purchased from Invitrogen.

2.2 Sequencing of EBIV genome 5' ends

EBIV were first concentrated by adding 3.2 g polyethylene glycol (PEG) 8000 (8%,

W/V, Millipore PEG8000, Sigma, USA) and 0.9 g NaCl (0.3 mol/L, Millipore Sigma, USA) to 40 mL virus supernatant (23). The suspension was mixed vigorously and incubated overnight at 4°C. Then the supernatant was discarded after centrifugation at 9000 × g for 30 min at 4°C. The pellet was resuspended in 200 µL PBS. Then the viral RNA was isolated using Trizol reagent (Invitrogen). First strand cDNA synthesis was carried out with one microgram RNA, Random Primer Mix (Takara) and 200 U SMARTScribe Reverse Transcriptase (Takara). EBIV M/L segment-specific sequences were amplified by PCR including Universal Primer A Mix (Takara), Gene-Specific Primers (GSPs) (M: 5'-GATTACGCCAAGCTTAGAACTAGTAGGTGGGGCTGCGAAG-3'; L: 5'-GATTACGCCAAGCTTGGACTAAGATGTTGACGCAGCAGGAT-3'), 2.5 µL cDNA and 1.25 U SeqAmp™ DNA polymerase (Takara). The PCR products were separated in a 1% agarose gel and recovered with a Gel extraction kit (Omega). While the PCR products were weak or smear bands, the PCR would be conducted again with diluted PCR products, Universal Primer Short and Nest Gene-Specific Primers (NGSPs) (M: 5'-GATTACGCCAAGCTTGTGCCATATCAGGACCCTGTGAGACC-3'; L: 5'-GATTACGCCAAGCTTGGAGGAGAAATGAGGAAGGCAATC-3'). Amplicons were cloned into vector pRACE (Takara) and individual clones were selected for nucleotide sequencing.

140

141 **2.3 Plasmid construction**

Full-length cDNA from the S, M, and L segments (GenBank accession no. KJ710423, KJ710424, KJ710425) was obtained by reverse transcription of EBIV RNA using GoScript™ Reverse Transcriptase (Promega, USA) and a pair of DNA primers complementary to the 5' and 3' end of the viral genomic RNAs. Complete cDNAs were sequence-amplified by PCR using KOD One™ PCR Master Mix -Blue- (TOYOBO, Japan) and were cloned into pSMART-LCK plasmid (Lucigen, Middleton, WI, USA) containing a T7 RNA polymerase promoter, hepatitis D ribozyme and T7 RNA polymerase terminator motif (abbreviated to pLCK), (24). As

149

shown in Fig. 1A, C and D, the resulting plasmids (pLCK-EBIV-S, pLCK-EBIV-M, and pLCK-EBIV-L) containing viral different segment sequences located between a T7 promoter and a hepatitis D ribozyme T7 polymerase terminator motif. In the plasmid pLCK-EBIV-eGFP/S, the *eGFP* gene was fused with the porcine teschovirus-1 2A peptide linker sequence (P2A), a together inserted before the ORF of EBIV S segment (Fig. 1B). The P2A peptide is a self-cleaving peptide allowing separate expression of two proteins via a ribosomal skipping event during its translation (25). The reporter virus rEBIV/eGFP/S was generated through the transfection of the plasmids (pLCK-EBIV-eGFP/S, pLCK-EBIV-M, and pLCK-EBIV-L) into BSR-T7 cells. All the constructs were confirmed by sequencing and submitted to the Genbank (Accession No: ON055165 to ON055168).




Fig 1. Structure diagram and transfection strategy of the recombinant plasmids rescue the recombinant EBIV. (A) The recombinant pLCK plasmid of S segment, named pLCK-EBIV-S. (B) Based on pLCK-EBIV-S, eGFP and P2A gene were added between 5' UTR and N protein ORF, named pLCK-EBIV-eGFP/S. (C) The recombinant plasmid of M segment, named pLCK-EBIV-M. (D) The recombinant pLCK plasmid of L segment named pLCK-EBIV-L. (E) Transfection strategy for rEBIV/WT and rEBIV/eGFP/S. Based on the pSMART-LCK plasmid, the pLCK plasmid were reconstructed by inserting the T7 promoter upstream the 5' UTR and HDV downstream the 3' UTR.

2.4 Virus rescue and plaque assay

173 Rescue of recombinant viruses was performed in BSR-T7 cells, which constitutively
174 express T7 polymerase. As shown in Fig 1E, a 50% confluent monolayer of BSR-T7
175 cells grown in 12-well plates was transfected with 300 ng pLCK-EBIV-S, 500 ng
176 pLCK-EBIV-M, and 700 ng pLCK-EBIV-L. When obvious cytopathic effect (CPE)
177 appeared, supernatants contained the rEBIV/WT were harvested.

178 For the rescue of reporter virus, the pLCK-EBIV-eGFP/S (500ng), which was the
179 substitute of pLCK-EBIV-S, was added in the transfection. At the next day post
180 transfection, the green fluorescence could be observed by the inverted fluorescent
181 microscope. The supernatants of cell culture were harvested at 120 h post transfection,
182 labeled as rEBIV/eGFP/S and stored at -80 °C.

183 The rescued viruses were subjected to a serial dilution of 10-fold with DMEM until
184 10^{-6} . Add 100 μ l virus diluent into each well of 24-well plates containing the
185 monolayer BHK-21. After 1 h incubation, the virus diluent was discarded, and each
186 well was were added with 500 μ l DMEM covering containing 1.5% methyl cellulose.
187 The cells would be cultured at 37 °C in 5% CO₂. Three days later, the cells were fixed
188 overnight with 3.7% formaldehyde and stained with 2% crystal violet for 15 min. The
189 amount and size of plaques were recorded.

190

191 **2.5 Immunofluorescence assay**

192 The EBIV-WT, rEBIV/WT and rEBIV/eGFP/S viruses were seeded on a 12-well
193 plate containing BHK-21 cell, respectively. After 24 hours, the cells were fixed in
194 cold (-20 °C) 100% methanol for 5 min at -20 °C and washed three times with PBS.
195 For the permeabilization, add the PBS containing 0.1% Triton X-100 and incubate
196 them for 15 min at room temperature. After that, wash them with PBS three times,
197 add the PBS containing 2% BSA, and incubated them for 60 min at room temperature.
198 Then the cells were incubated with the mouse polyclonal antibody against EBIV-NP
199 (1:250 diluted in PBS containing 0.1% BSA) overnight at 4°C. After washing with
200 PBS three times, the cells were incubated with goat anti-mouse IgG conjugated with
201 Alexa Fluor 594 (1:250 diluted in PBS with 0.1% BSA) at room temperature for 1 h
202 (avoid light). Following three times of PBS washing, the DAPI was added to the cells,

203 and keep in for 5 min at room temperature. Then the fluorescence signal of each well
204 was observed and analyzed under an Olympus fluorescence microscope at 200 ×
205 magnification (26).

206

207 **2.6 Viral growth kinetics**

208 To compare the differences in replication among the three viruses, the growth kinetics
209 of EBIV-WT, rEBIV/WT and rEBIV/eGFP/S viruses on BHK-21 were examined
210 respectively. Approximately 1×10^4 BHK-21 cells were seeded in a 17.5 mm dish.
211 After incubation overnight, the cells were infected with 1mL EBIV-WT, rEBIV/WT
212 or rEBIV/eGFP/S virus at MOI of 0.01. After incubation for one hours, the
213 supernatants were collected, the cells were washed with PBS for three times and
214 replaced with fresh medium with 2% FBS. Every 24 hours post infection, the
215 supernatants were collected and stored at -80°C . At last, they were subjected to
216 plaque assay to determine the viral titer. For rEBIV/eGFP/S infection, the expression
217 of eGFP gene was observed under the fluorescence microscope at 100 ×
218 magnification.

219

220 **2.7 Stability of the rEBIV/eGFP/S virus in cell culture**

221 To analyze whether the eGFP reporter gene can be stable presence during the passage,
222 the rEBIV/eGFP/S virus was serially passaged in vertebrate-derived BHK-21 cells for
223 ten rounds respectively. For each generation, 200 μL viruses were used to infect naïve
224 BHK-21 cells, and the percentage of cells expressing eGFP was evaluated at 24-48
225 hpi (hour post infection) after each passage. In addition, the RNAs of the infected
226 cells were extracted in each passage and separated into two parts, one subjected to
227 RT-PCR using PrimeScript™ One Step RT-PCR Kit Ver.2 (Dye Plus) (Takara,
228 Japan), then the region between S-5'UTR and N protein-ORF genes was amplified to
229 monitor the expression of eGFP.

230 The rest of RNAs were performed with real-time reverse transcription PCR
231 (RT-qPCR) using a Luna® Universal Probe One-Step RT-qPCR Kit (New England
232 Biolabs) according to the manufacturer's recommendations by a thermocycler

(BIO-RAD CFX96™ Real-Time System). The primers for RT-qPCR targeted the N protein (S segment) of EBIV, including EBIV-NP-F (5'-GGTACCTCTGGCGCATTGTCTTTTC-3'), EBIV-NP-R (5'-GAAAAATGGCATCACCTGGGAAAGT-3'), and EBIV-NP-Probe (5'-FAM-TTTTGGGTCCATCTCTTTCTCTGC-BHQ1-3'). Both of primers were synthesized by TSINGKE (Wuhan Branch, China). Twenty microliter reaction mixtures containing 2 µL of viral RNA and 0.8 µL of each primer were incubated at 55 °C for 10 min and 95 °C for 1 min followed by 40 cycles of 95 °C for 10 s and 55 °C for 30 s.

241

242 **2.8 Cell tropism of rEBIV/eGFP/S**

243 Cells from different sources, including Vero E6, SW13, PK15, LMH and C6/36 cells, 244 were seeded in 6-well plates, respectively. After incubated overnight the cells were 245 infected with the rEBIV/eGFP/S virus at MOI of 0.1. After 1 h incubation in 37 °C, 246 the virus diluent was discarded, and fresh cell culture medium was added then 247 cultured at 37 °C. The cells would be observed and taken the pictures were taken 248 every day (from day 0 to day 7) to record the virus infection.

249

250 **2.9 High-content Screening assay conditions**

251 The cell density, infective dose, and assay endpoint were the same as the previous 252 described (27). Cell densities (10,000 cells per well) of BHK-21 cells were infected at 253 MOI values 0.01. And two drugs Ribavirin and Favipiravir were serially diluted 254 ranging from 50 µM to 0.78125 µM to obtain the EC50. Fluorescent signal was 255 detected by Operetta imaging system (Perkin Elmer) at 36 h after rEBIV/eGFP/S 256 inoculation, and the cell viability was detected under a microscope at the same time. 257 Statistical calculations of Z'-values were made as follows: $Z' = 1 - (3SD \text{ of sample} + 3SD \text{ of control}) / (|Mean \text{ of sample} - Mean \text{ of control}|)$ (28). Here, SD is the standard 258 deviation of the fluorescent signals from cell control or sample. Z' value is 259 meaningful within the range of $-1 < Z' \leq 1$, the larger the value the higher the data 260 quality, and between 0.5 and 1 are considered good quality. Then the experiment was 261 repeated on EBIV-WT by plaque assay to confirm the antiviral results. 262

263 A library of 96 compounds from natural extracts was purchased from Weikeqi
264 Biotech (Sichuan, China). Compounds were stored as 20 mM stock solutions in
265 DMSO at -80°C until use. BHK-21 cells were dissociated and seeded at a density of
266 1×10^4 cells per well in 96-well plates. After overnight incubation, cell monolayers
267 were treated with the compounds at a final concentration of 10 μM and at the same
268 time infected with the rEBIV/eGFP/S at the MOI of 0.01. DMEM with 2% FBS and
269 0.1% DMSO was negative control, and 50 μM Ribavirin was used as positive control.
270 After 36 h incubation, the fluorescent signal in all wells was detected by Operetta
271 imaging system (PerkinElmer) and the Z' factor was calculated and analyzed.

272

273 **3 Result**

274 **3.1 Construction and characterization of rEBIV/WT and rEBIV/eGFP/S**

275 We constructed an infectious cDNA clone of EBIV which was isolated from *Culex*
276 *modestus* mosquitoes in 2014 in Xinjiang (20). As depicted in Fig. 1A, C, D, three
277 segments covering the complete genome sequence of EBIV were chemically
278 synthesized and then cloned into a low-copy-number vector as described in materials
279 and methods. We also designed the EBIV reporter virus with eGFP gene using the
280 similar strategy used for CCHFV/ZsG reporter virus (29). The eGFP gene with P2A
281 was inserted between the 5' UTR and N protein-ORF region of pLCK-EBIV-S (Fig.
282 1B). The resulted clone was designated as pLCK-EBIV-eGFP/S as described in
283 materials and methods.

284 The two group of transcription plasmids (one is pLCK-EBIV-S + pLCK-EBIV-M +
285 pLCK-EBIV-L, while another is pLCK-EBIV-eGFP/S + pLCK-EBIV-M +
286 pLCK-EBIV-L, as shown in Fig. 1E) were transfected into BSR-T7 cells, respectively,
287 to test the viral rescue function of the infectious clone. The supernatants were
288 collected every day (called rEBIV/WT and rEBIV/eGFP/S) and subjected to plaque
289 assay to determine the plaque morphology. EBIV-WT, rEBIV/WT and rEBIV/eGFP/S
290 were seeded in BHK-21 cells respectively at MOI=0.01 for virus production, one
291 plate with three viruses were fixed at 24 hpt (hour post transfection) and subjected to

292 IFA using specific antibody against EBIV N protein to detect viral protein synthesis.
 293 The supernatants from another plate with three viruses were collected every day and
 294 their titer were determined to study the growth dynamics of three viruses.

295 As shown in Fig. 2A and 2B, when transfected the transcription plasmids for rEBIV,
 296 the CPE appeared at 24 hpt and got obvious at 48 hpt. While for rEBIV/eGFP/S,
 297 although the bright green fluorescence could be observed on the second day of
 298 transfection, the CPE appeared on the 4 dpt, and got apparent on 5 dpt (SFig 1). The
 299 rescue efficiency could get to 70% (positive detection in 7 of 10 replica wells) in once
 300 successive rescue experiment (results not shown). The IFA results showed (Fig. 2C)
 301 that the IFA-positive cells of rEBIV/WT were almost 100% among the infected cells
 302 at 24 hpt, which was similar to EBIV-WT, while the rEBIV/eGFP/S showed less
 303 IFA-positive cells at 24 hpt.

304 The viral plaque morphology for rEBIV/WT measured at different time points were
 305 homogeneously large in BHK-21 cells, besides, both shape and size seemed similar to
 306 that of wild type virus. On the other hand, the rEBIV/eGFP/S displayed obviously
 307 smaller plaques than EBIV-WT and rEBIV (Fig. 2D). At the same time, the viral
 308 growth kinetics (Fig. 2E) showed the rEBIV/WT exhibited indistinguishable patterns
 309 of replication with wild type virus in BHK-21, whereas the viral productions of
 310 rEBIV/eGFP/S were about 100-fold lower than that of wild type virus at the same
 311 MOI.

312 These results demonstrated that these two rescued viruses both recovered by the
 313 infectious clone replicated efficiently. However, differences in IFA positive rate, viral
 314 plaques morphology and viral kinetics between EBIV-WT and rEBIV/eGFP/S,
 315 illustrate that the insertion of the eGFP reporter gene into EBIV genome affected the
 316 viral replication in BHK-21 cell.




Fig 2. Characterization of wild type EBIV, rEBIV/WT and rEBIV/eGFP/S. (A) the cell state at 48 hpt. (B) Analysis of eGFP expression in the BSR-T7 cells and the expression of eGFP was detected under a fluorescent microscope at the 48 hpt. (C) IFA of viral protein expression in BHK-21 cells infected with the three viruses. IFA was performed at the 24 hpi using the antibody against the N protein. (D) Plaque morphology of the three viruses. (E) Growth kinetics curves of wild type EBIV, rEBIV/WT and rEBIV/eGFP/S.

3.2 Stability of the rEBIV/eGFP/S virus in cell culture

To analyze whether the eGFP reporter gene can be stably maintained in cell culture, the rEBIV/eGFP/S virus was serially passaged in BHK-21 cells for ten rounds. As shown in Fig. 3A, all of the BHK-21 cells infected by P1-P10 reporter viruses showed

strong fluorescence signals and nearly 100% were eGFP positive when the apparent CPE appeared, indicating the eGFP gene was stably maintained during passaging. In addition, for each passage, the RNAs of the infected cells were extracted and subjected to RT-PCR to test gene stability. Different sizes of bands were expectedly detected for WT (151 bp) and reporter virus (868 bp) as the insertion of the eGFP gene (Fig. 4B). Each of the P1-P10 RNAs extracted from BHK-21 cells displayed a specific band showing no sequence deletion within the reporter gene which is confirmed by sequencing, further suggesting the stability of the reporter virus in BHK-21 cells.




Fig 3 Genetic stability of rEBIV/eGFP/S in BHK-21 cells. (A) The eGFP expression of the different passages of rEBIV/eGFP/S in BHK-21 cell. The rEBIV/eGFP/S was serially passaged in BHK-21 cells for ten rounds. The expression of eGFP was detected under a fluorescent microscope at 48 h after infection. (B) Detection of the eGFP gene during virus passage in BHK-21 cell. Total RNAs from the infected cells were extracted and subjected to RT-PCR detection using the primers spanning 5'UTR to N protein gene that include the complete eGFP gene. The resulting RT-PCR products were resolved by 1% agarose gel electrophoresis. (C) The


349 titer of 1st to 10th generation of rEBIV/eGFP/S. The virus titers were calculated by
350 RT-qPCR results.

351

352 **3.3 Wide cell tropism and efficient replication in different cell cultures**

353 To further confirm the viral infectivity to cells of different origin, five cell lines were
354 selected and inoculated with the rEBIV/eGFP/S at MOI=0.1. Pictures were taken
355 from D1 to D10 to observe fluorescence in cell. As shown in Fig 4, all five cell lines
356 could be infected by rEBIV/eGFP/S, but with different sensitivities. LMH cells were
357 highly susceptible to rEBIV/eGFP/S, suggesting that EBIV could be transmitted
358 among avian species, which consistent with previous reports (22). Besides, the
359 rEBIV/eGFP/S is also high infectious to C6/36 cells, just as we speculated, since
360 EBIV is an arbovirus that isolated from mosquitoes. However, SW13, Vero E6 and
361 PK15 showed a bit lower susceptible to rEBIV/eGFP/S when compared to LMH and
362 C6/36 cells.

363



364

365 Fig. 4. Cell lines derived from human, monkey, pig, avian, and mosquito infected
366 with rEBIV/eGFP/S.


367

368 **3.4 Antiviral activity evaluation based on the rEBIV/eGFP/S reporter virus**

369 Ribavirin and favipiravir (also known as T-705) were both broad-spectrum antiviral
370 drugs that found to inhibit the RdRp of RNA viruses (30)(31), and had been reported
371 to have inhibitory effect on several orthobunyaviruses replication, such as LACV

(32)(33), BUNV (34), Jamestown Canyon virus (JCV) (33). In order to validate the utility of rEBIV/eGFP/S reporter virus for antiviral screening, we compared the antiviral ability of ribavirin and favipiravir on rEBIV/eGFP/S. BHK-21 cells were infected with rEBIV/eGFP/S at an MOI of 0.01 and respectively treated with different final concentrations of ribavirin and favipiravir (0 μ M-50 μ M) at the same time. At 36 hpi, the fluorescence value was read by Operetta imaging system (PerkinElmer), and the cell viability was detected under a microscope. The inhibition rate was derived from the ratio of the fluorescence value of the concentration to the negative contrast from the fluorescence number of each concentration minus the negative contrast, and divided by the negative contrast. The inhibition rate in the rEBIV/eGFP/S infected BHK-21 increased dramatically in a dose-dependent manner of ribavirin (Fig. 5A). The EC₅₀ of ribavirin calculated by inhibition rate was 21.91 μ M. However, the favipiravir was inactive against rEBIV/eGFP/S even at 50 μ M (Fig. 5B), which is similar with the wild type EBIV (Fig. 5C, D). These results indicated that the anti-EBIV activity of compound can be rapidly evaluated by eGFP signal detection of the rEBIV/eGFP/S infected cells.

We further chose 25 μ M ribavirin as positive control, and tested the anti-rEBIV/eGFP/S activity of the library of compounds from nature product. The BHK-21 cells were infected with rEBIV/eGFP/S at an MOI of 0.01 and treated with various compounds (10 μ M). The fluorescence value was read at 36 hpi, and the cell viability was observed at the same time. The Z' factor of the positive and negative control is 0.46, indicates that this model is not very good but acceptable. As depicted in Fig. 5C and several compounds showed a significant inhibitory effect on rEBIV/eGFP/S replication with higher Z factors (the raw data of the screening is in STable). The wells with Clinodiside A, Diosmin, Secoxyloganin, Disoglucide, and Cyanidin-3-O-glucoside showed both high Z factors and 100% cell viability, proving they may be potential effective anti-EBIV drugs. Overall, these results demonstrated that the rEBIV/eGFP/S reporter virus provides a rapid and precise tool for antiviral inhibitors screening against EBIV.



401
402 **Fig. 5 Antiviral activity of ribavirin, favipiravir and some medicines on**
403 **rEBIV/eGFP/S.** (A) Inhibition rate of different concentrations of ribavirin (0-50 μM)
404 on the eGFP expression of the rEBIV/eGFP/S infected cells at 36 hpi. The EC₅₀ was
405 calculated by nonlinear regression using Prism software (GraphPad) as shown was

21.91 μ M. Error bars indicate the standard deviations from three independent experiments. (B) Inhibition rate of rEBIV/eGFP/S infected BHK-21 cells treated with different concentrations of favipiravir. And favipiravir had no inhibitory effect on rEBIV/eGFP/S. (C), (D) Inhibition rate of different concentrations of ribavirin and favipiravir (0-50 μ M) on wild type EBIV, tested by plaque assay. (E) The library of compounds was scanned, and the Z factor of each compound and positive control were obtained by the fluorescence value. The compounds that had higher Z factor than positive controls were shown in the table. The different colors and sizes of circles indicated their respective cell viability.

415

416 **4 Discussion**

EBIV as a newly classified orthobunyavirus as a new species in the *Peribunyaviridae* showed potential threat to human or animal health. In order to develop reliable tools for EBIV study, here we successfully constructed the infectious clones of EBIV and an eGFP reporter virus rEBIV/eGFP/S. By the standard virus rescue procedure, we identified that the rEBIV/WT virus showed indistinguishable replication efficiency with the wild type EBIV (Cu20-XJ) in BHK-21 cells, while the insertion of eGFP reduced the replication efficiency. The eGFP gene expression level within the rEBIV/eGFP/S infected cells correlated well with the viral replication, inferring that the growth of reporter virus can be monitored directly by eGFP observation. The rEBIV/eGFP/S could stably passage in BHK-21 cells and show different tropism on cell lines of different sources. After validating the same medicines (ribavirin and favipiravir) had the same inhibitory effect on both wild type EBIV and rEBIV/eGFP/S in BHK-21, we confirmed the feasibility of the rEBIV/eGFP/S for rapid antiviral screening assay, and five compounds were found to have an inhibitory effect on the EBIV.

In our study, the eGFP gene was first inserted into the N or C-terminal of N protein directly, however, neither approach rescued the virus. We considered that this may because the eGFP affected the normal expression and native structure of N protein, leading to the failure of the virus to replicate and package normally. Then we added

436 P2A between eGFP and N protein, allowing separate expression of these two proteins,
 437 to get infectious rEBIV/eGFP/S. But the results of plaque assays and growth curves
 438 suggested that the virus was significantly different from the wild type, possibly
 439 because of the insertion of eGFP may affect the expression of NSs protein, which has
 440 multiple functions in the viral replication cycle and is the major virulence factor (35)
 441 but dispensable for virus growth (36)(37). We also tried to insert the P2A with eGFP
 442 between 3' UTR and N protein ORF, but also failed. The reason would be when the N
 443 protein precedes P2A, it will carry more than 20 amino acid tails during translation
 444 shearing, which may affect the function of N protein. As for other two segments, there
 445 has been successful rescued cases on M segment in Bunyamwera virus (38), which
 446 replaced almost half of the N terminal of Gc to eGFP. However, insert report gene to
 447 L segment has not been studied yet, which may due to the large size of L and potential
 448 difficulty to modify the RdRp and preserving its polymerase activity.

449 To evaluate the rEBIV/eGFP/S stability in both mammalian and mosquito cell lines,
 450 we also did continuous passages of rEBIV/eGFP/S on C6/36 cells. To our surprise,
 451 although the fluorescence could be observed and the eGFP gene could be detected by
 452 RT-PCR using specific eGFP primers, the eGFP gene seemed to switch places since
 453 the bands significantly shorter when using the primers for sequences outside the eGFP
 454 from the second generation (SFig 2). The similar gene loss with unknown mechanism
 455 has been reported in other viruses in C6/36 cells(39)(40)(41), we speculated that due
 456 to the different replication mechanisms of EBIV between mammalian and insect cells,
 457 the insertion of an additional ORF into the viral genome may affect RNA replication
 458 and the stability of inserted gene in C6/36 but not in BHK-21 cells. Further work is
 459 needed to test this hypothesis.

460 Ribavirin is the first synthetic nucleoside analogue that has ever been reported to be
 461 active against a broad spectrum of RNA viruses (such as hepatitis C virus (HCV),
 462 Respiratory Syncytial Virus (RSV), and influenza virus) (42). And it can also reduce
 463 the replication of EBIV, and the EC₅₀ of rEBIV/eGFP/S is 21.91 μ M which is similar
 464 to BUNV-mCherry (34). Favipiravir triphosphate shows broad-spectrum inhibitory
 465 activities against the RNA polymerases of influenza A viruses (including the highly

pathogenic H5N1 viruses) (43) and many other positive-sense RNA (such as West Nile virus (WNV) and Western equine encephalitis (WEE)) and negative-sense RNA viruses (such as Crimean-Congo hemorrhagic fever virus (CCHFV), Severe fever with thrombocytopenia syndrome virus (SFTSV), Rift valley fever virus (RVFV), and Ebola virus) (31). But in our study, the favipiravir is ineffective even at higher concentrations, the specific reasons need to be further explored. As for the antiviral candidates we found in this research, diosmin and cyanidin-3-O-glucoside were identified as inhibitor of SARS-CoV-2, since diosmin could bind covalently to the SARS-CoV-2 main protease, inhibiting the infection pathway of SARS-CoV-2 (44), and cyanidin-3-O-glucoside was demonstrated to inhibit M protein activity of SARS-CoV-2 in a dose-dependent manner at biologically relevant (μM) concentrations (45). The other three compounds, clinodiside A, secoxyloganin and disoglucoside, have not been reported to have antiviral effects yet. More antiviral mechanisms and minimum effective dose need to be further studied.

In conclusion, we have established the reverse genetic system for EBIV, and rescued a reporter virus rEBIV/eGFP/S. The reporter virus showed good stability in BHK-21 cell and different tropism in various cell lines. The reporter virus based antiviral assay developed in this study will facilitate the antiviral screening for novel anti-EBIV agents.

485

486 **Funding**

487 This work was supported by the Wuhan Science and Technology Plan Project
488 (2018201261638501)

489

490 **Author Contributions**

491 HX and ZY designed the experiments. NR, FW, LZ, LW, and JQ performed the
492 experiments. NR, FW, and JQ analyzed the data. GZ, EB, and BZ contributed the
493 reagents, materials, and analysis tools. NR, FW, EB, ZY and HX wrote and review the
494 manuscript. All authors contributed to the article and approved the submitted version.

495

496 Acknowledgments

497 We would like to thank the valuable suggestions from Prof. Ke Peng (Wuhan Institute
498 of Virology) and Dr. Shufen Li (Wuhan Institute of Virology) to our experiment, and
499 Ding Gao and An-Na Du from the Core Facility and Technical Support, Wuhan
500 Institute of Virology, for their help with HCS.

501

502 Reference

- 503 1. Dong X, Soong L. Emerging and Re-emerging Zoonoses are Major and Global
504 Challenges for Public Health. *Zoonoses*. 2021;1(1):7–8.
- 505 2. Abudurexiti A, Adkins S, Alioto D, Alkhovsky S V., Avšič-Županc T,
506 Ballinger MJ, et al. Taxonomy of the order Bunyavirales: update 2019. *Arch*
507 *Viro*. 2019;164(7):1949–65.
- 508 3. Hughes HR, Adkins S, Alkhovskiy S, Beer M, Blair C, Calisher CH, et al.
509 ICTV virus taxonomy profile: Peribunyaviridae. *J Gen Virol*. 2020;101(1):1–2.
- 510 4. Elliott RM. Orthobunyaviruses: recent genetic and structural insights. *Nat Rev*
511 *Microbiol* [Internet]. 2014;12(10):673–85. Available from:
512 <http://dx.doi.org/10.1038/nrmicro3332>
- 513 5. Sakkas H, Bozidis P, Franks A, Papadopoulou C. Oropouche fever: A review.
514 *Viruses*. 2018 Apr 1;10(4).
- 515 6. Harding S, Greig J, Mascarenhas M, Young I, Waddell LA. La Crosse virus: A
516 scoping review of the global evidence. *Epidemiol Infect* [Internet]. 2019;147.
517 Available from: <https://doi.org/10.1017/S0950268818003096>
- 518 7. Fausta Dutuze M, Nzayirambaho M, Mores CN, Christofferson RC. A Review
519 of Bunyamwera, Batai, and Ngari viruses: Understudied Orthobunyaviruses
520 with potential one health implications. *Front Vet Sci*. 2018;5(APR):1–9.
- 521 8. Brenner J, Behar A. Simbu viruses' infection of livestock in israel—a transient
522 climatic land. *Viruses* [Internet]. 2021;13(11). Available from:
523 <https://doi.org/10.3390/v13112149>
- 524 9. Beer M, Conraths FJ, Van Der Poel WHM. “Schmallenberg virus” - A novel
525 orthobunyavirus emerging in Europe. *Epidemiol Infect* [Internet].
526 2013;141(1):1–8. Available from: <https://doi.org/10.1017/S0950268812002245>
- 527 10. Oymans J, Schreur PJW, Van Oort S, Vloet R, Venter M, Pijlman GP, et al.
528 Reverse genetics system for shuni virus, an emerging orthobunyavirus with
529 zoonotic potential. *Viruses*. 2020;12(4):1–12.
- 530 11. Kraatz F, Wernike K, Reiche S, Aebischer A, Reimann I, Beer M.
531 Schmallenberg virus non-structural protein NSm: Intracellular distribution and
532 role of non-hydrophobic domains. *Virology* [Internet]. 2018;516(December
533 2017):46–54. Available from: <https://doi.org/10.1016/j.virol.2017.12.034>
- 534 12. Ariza A, Tanner SJ, Walter CT, Dent KC, Shepherd DA, Wu W, et al.
535 Nucleocapsid protein structures from orthobunyaviruses reveal insight into
536 ribonucleoprotein architecture and RNA polymerization. *Nucleic Acids Res*.
537 2013;41(11):5912–26.

- 538 13. Van Knippenberg I, Carlton-Smith C, Elliott RM. The N-terminus of
539 Bunyamwera orthobunyavirus NSs protein is essential for interferon
540 antagonism. *J Gen Virol.* 2010;91(8):2002–6.
- 541 14. Barry G, Varela M, Ratnien M, Blomström AL, Caporale M, Seehusen F, et al.
542 NSs protein of Schmallenberg virus counteracts the antiviral response of the
543 cell by inhibiting its transcriptional machinery. *J Gen Virol.* 2014;95(PART
544 8):1640–6.
- 545 15. Dunlop JI, Szemiel AM, Navarro A, Wilkie GS, Tong L, Modha S, et al.
546 Development of reverse genetics systems and investigation of host response
547 antagonism and reassortment potential for Cache Valley and Kairi viruses, two
548 emerging orthobunyaviruses of the Americas. *PLoS Negl Trop Dis.*
549 2018;12(10):1–22.
- 550 16. Lowen AC, Noonan C, McLees A, Elliott RM. Efficient bunyavirus rescue
551 from cloned cDNA. *Virology.* 2004;330(2):493–500.
- 552 17. Elliott RM, Blakqori G, van Knippenberg IC, Koudriakova E, Li P, McLees A,
553 et al. Establishment of a reverse genetics system for Schmallenberg virus, a
554 newly emerged orthobunyavirus in Europe. *J Gen Virol.*
555 2013;94(PART4):851–9.
- 556 18. Blakqori G, Weber F. Efficient cDNA-Based Rescue of La Crosse
557 Bunyaviruses Expressing or Lacking the Nonstructural Protein NSs. *J Virol.*
558 2005;79(16):10420–8.
- 559 19. Ogawa Y, Sugiura K, Kato K, Tohya Y, Akashi H. Rescue of Akabane virus
560 (family Bunyaviridae) entirely from cloned cDNAs by using RNA polymerase
561 I. *J Gen Virol.* 2007;88(12):3385–90.
- 562 20. Liu R, Zhang G, Yang Y, Dang R, Zhao T. Genome sequence of Abbey Lake
563 virus, a novel orthobunyavirus isolated from China. *Genome Announc.*
564 2014;2(3):13845.
- 565 21. Xia H, Liu R, Zhao L, Sun X, Zheng Z, Atoni E, et al. Characterization of
566 Ebinur Lake Virus and Its Human Seroprevalence at the China–Kazakhstan
567 Border. *Front Microbiol.* 2020;10(January):1–11.
- 568 22. Zhao L, Luo H, Huang D, Yu P, Dong Q, Mwaliko C, et al. Pathogenesis and
569 Immune Response of Ebinur Lake Virus: A Newly Identified Orthobunyavirus
570 That Exhibited Strong Virulence in Mice. *Front Microbiol.* 2021;11(February).
- 571 23. Miura T, Masago Y, Sano D, Omura T. Development of an effective method
572 for recovery of viral genomic RNA from environmental silty sediments for
573 quantitative molecular detection. *Appl Environ Microbiol* [Internet].
574 2011;77(12):3975–81. Available from: <https://journals.asm.org/journal/aem>
- 575 24. Zivcec M, Metcalfe MG, Albarrino CG, Guerrero LW, Pegan SD, Spiropoulou
576 CF, et al. Assessment of Inhibitors of Pathogenic Crimean-Congo Hemorrhagic
577 Fever Virus Strains Using Virus-Like Particles. *PLoS Negl Trop Dis.*
578 2015;9(12):1–23.
- 579 25. Kim JH, Lee SR, Li LH, Park HJ, Park JH, Lee KY, et al. High cleavage
580 efficiency of a 2A peptide derived from porcine teschovirus-1 in human cell
581 lines, zebrafish and mice. *PLoS One.* 2011;6(4):1–8.

- 582 26. Deng CL, Liu SQ, Zhou DG, Xu LL, Li XD, Zhang PT, et al. Development of
583 neutralization assay using an eGFP chikungunya virus. *Viruses*.
584 2016;8(7):1–16.
- 585 27. Li JQ, Deng CL, Gu D, Li X, Shi L, He J, et al. Development of a replicon cell
586 line-based high throughput antiviral assay for screening inhibitors of Zika virus.
587 *Antiviral Res* [Internet]. 2018;150(August 2017):148–54. Available from:
588 <https://doi.org/10.1016/j.antiviral.2017.12.017>
- 589 28. Zhang JH, Chung TDY, Oldenburg KR. A simple statistical parameter for use
590 in evaluation and validation of high throughput screening assays. Vol. 4,
591 *Journal of Biomolecular Screening*. 1999. p. 67–73.
- 592 29. Welch SR, Scholte FEM, Flint M, Chatterjee P, Nichol ST, Bergeron É, et al.
593 Identification of 2'-deoxy-2'-fluorocytidine as a potent inhibitor of
594 Crimean-Congo hemorrhagic fever virus replication using a recombinant
595 fluorescent reporter virus. *Antiviral Res* [Internet]. 2017;147(September):91–9.
596 Available from: <http://dx.doi.org/10.1016/j.antiviral.2017.10.008>
- 597 30. De Clercq E, Li G. Approved antiviral drugs over the past 50 years. *Clin*
598 *Microbiol Rev*. 2016;29(3):695–747.
- 599 31. Furuta Y, Komeno T, Nakamura T. Favipiravir (T-705), a broad spectrum
600 inhibitor of viral RNA polymerase. *Proc Japan Acad Ser B Phys Biol Sci*
601 [Internet]. 2017;93(7):449–63. Available from:
602 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5713175/pdf/pjab-93-449>
- 603 32. Gowen BB, Wong MH, Jung KH, Sanders AB, Mendenhall M, Bailey KW, et
604 al. In vitro and in vivo activities of T-705 against arenavirus and bunyavirus
605 infections. *Antimicrob Agents Chemother*. 2007;51(9):3168–76.
- 606 33. Kato H, Takayama-Ito M, Satoh M, Kawahara M, Kitaura S, Yoshikawa T, et
607 al. Favipiravir treatment prolongs the survival in a lethal mouse model
608 intracerebrally inoculated with Jamestown Canyon virus. *PLoS Negl Trop Dis*
609 [Internet]. 2021;15(7):e0009553. Available from:
610 <http://dx.doi.org/10.1371/journal.pntd.0009553>
- 611 34. Ter Horst S, Fernandez-Garcia Y, Bassetto M, Günther S, Brancale A, Neyts J,
612 et al. Enhanced efficacy of endonuclease inhibitor baloxavir acid against
613 orthobunyaviruses when used in combination with ribavirin. *J Antimicrob*
614 *Chemother*. 2020;75(11):3189–93.
- 615 35. Eifan S, Schnettler E, Dietrich I, Kohl A, Blomström AL. Non-structural
616 proteins of arthropod-borne bunyaviruses: Roles and functions. *Viruses*.
617 2013;5(10):2447–68.
- 618 36. Varela M, Schnettler E, Caporale M, Murgia C, Barry G, McFarlane M, et al.
619 Schmallenberg Virus Pathogenesis, Tropism and Interaction with the Innate
620 Immune System of the Host. *PLoS Pathog*. 2013;9(1).
- 621 37. Bridgen A, Weber F, Fazakerley JK, Elliott RM. Bunyamwera bunyavirus
622 nonstructural protein NSs is a nonessential gene product that contributes to
623 viral pathogenesis. *Proc Natl Acad Sci U S A*. 2001;98(2):664–9.
- 624 38. Shi X, van Mierlo JT, French A, Elliott RM. Visualizing the Replication Cycle
625 of Bunyamwera Orthobunyavirus Expressing Fluorescent Protein-Tagged Gc

626 Glycoprotein. *J Virol.* 2010;84(17):8460–9.

627 39. Zhang ZR, Zhang HQ, Li XD, Deng CL, Wang Z, Li JQ, et al. Generation and
628 characterization of Japanese encephalitis virus expressing GFP reporter gene
629 for high throughput drug screening. *Antiviral Res.* 2020;182(January).

630 40. Suphatrakul A, Duangchinda T, Jupatanakul N, Prasittisa K, Onnoms S,
631 Pengon J, et al. Multi-color fluorescent reporter dengue viruses with improved
632 stability for analysis of a multi-virus infection. *PLoS One.* 2018;13(3):1–19.

633 41. Li X, Zhang H, Zhang Y, Li J, Wang Z, Deng C, et al. Development of a rapid
634 antiviral screening assay based on eGFP reporter virus of Mayaro virus.
635 *Antiviral Res [Internet].* 2019;168(March):82–90. Available from:
636 <https://doi.org/10.1016/j.antiviral.2019.05.013>

637 42. Sidwell R, Huffman J, Khare G, Allen L, Witkowski J, Robins R. Broad
638 spectrum antiviral activity of Virazole: 1-beta
639 Dribofuranosyl-D-Broad-spectrum antiviral activity of Virazole: 1-beta
640 Dribofuranosyl,. *Science (80-).* 1972;177(1971):705–6.

641 43. Kiso M, Takahashi K, Sakai-Tagawa Y, Shinya K, Sakabe S, Le QM, et al.
642 T-705 (favipiravir) activity against lethal H5N1 influenza A viruses. *Proc Natl*
643 *Acad Sci U S A.* 2010;107(2):882–7.

644 44. Farhat N, Khan AU. Repurposing drug molecule against SARS-Cov-2
645 (COVID-19) through molecular docking and dynamics: a quick approach to
646 pick FDA-approved drugs. *J Mol Model [Internet].* 2021;27(11):1–11.
647 Available from: <https://doi.org/10.1007/s00894-021-04923-w>

648 45. Liang J, Pitsillou E, Ververis K, Guallar V, Hung A, Karagiannis TC. Small
649 molecule interactions with the SARS-CoV-2 main protease: In silico all-atom
650 microsecond MD simulations, PELE Monte Carlo simulations, and
651 determination of in vitro activity inhibition. *J Mol Graph Model.*
652 2022;110(January):293.

653

654